cort-125134
Small moleculeexperimental
Clinical trial activity
10 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2014 (NCT03508635)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorANTAGONIST
NR3C1 antagonist
Ph1 trial initiated in Septemebr 2014, no trial ID found.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544957 ↗
Also known as
- cort125134
- cort125134
- cort 125134
- cort-125134
- cort-125134
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06094738 | Phase 1 | Sep 19, 2020 | Corcept Therapeutics |
| NCT03674814 | Phase 1 | Nov 10, 2018 | Corcept Therapeutics, National Cancer Institute (NCI), University of Chicago |
| NCT03604198 | Phase 2 | May 7, 2018 | Corcept Therapeutics |
| NCT03442621 | Phase 1 | Jan 16, 2018 | Corcept Therapeutics |
| NCT06094790 | Phase 1 | May 18, 2017 | Corcept Therapeutics |
| NCT03067376 | Phase 1 | Aug 1, 2016 | Corcept Therapeutics, Quotient |
| NCT02804750 | Phase 2 | Jun 1, 2016 | Corcept Therapeutics |
| NCT06094712 | Phase 1 | Apr 7, 2016 | Corcept Therapeutics |
| NCT02762981 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2016 | Corcept Therapeutics |
| NCT03508635 | Phase 1 | Sep 30, 2014 | Corcept Therapeutics, Quotient |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corcept Therapeutics | For profit | 10 | 9 | 2 | 2014 |
| Quotient | For profit | 2 | 0 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2018 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1